ABCL vs XBIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 12, 2026

ABCL

52.4
AI Score
VS
XBIO Wins

XBIO

54.1
AI Score

Investment Advisor Scores

ABCL

52score
Recommendation
HOLD

XBIO

54score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric ABCL XBIO Winner
Revenue 23.00M 1.47M ABCL
Net Income -139.35M -1.39M XBIO
Net Margin -605.8% -94.5% XBIO
Operating Income -173.62M -1.47M XBIO
ROE -13.1% -22.8% ABCL
ROA -9.3% -19.9% ABCL
Total Assets 1.50B 6.97M ABCL
Current Ratio 12.43 7.43 ABCL

Relative Price Performance (Last 90 Days)

ABCL 1M: -5.2% · 3M: +8.9% XBIO 1M: -11.1% · 3M: -43.3%

Current Technical Phase

ABCL

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 48

RSI (14): 48.4 · Price: $11.95

XBIO

Markdown
Sell / avoid

Price below a falling SMA50 (slope -19.7%), weak momentum, RSI 40

RSI (14): 39.9 · Price: $1.87

Fundamentals Snapshot

Metric ABCL XBIO
Market Cap — —
Forward P/E -16.1 -5.5
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth -0.8% 0.1%
Gross Margin -2.0% 1.0%
Operating Margin -15.5% -1.5%
EPS -0.48 -1.13
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, XBIO is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.